Navigation Links
Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009
Date:2/17/2009

considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

                       - Financial Statements Follow -



          GENESIS PHARMACEUTICALS ENTERPRISES, INC. AND SUBSIDIARIES

       CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME
                                 (UNAUDITED)

                       For the Three Months Ended   For the Six Months Ended
                              December 31,                 December 31,
                           2008          2007          2008          2007
    REVENUES:
      Sales            $32,944,809  $25,154,071    $60,265,493  $40,416,860
      Sales -
       related
       parties                  --    1,394,662        243,909    2,742,757
    TOTAL REVENUES      32,944,809   26,548,733     60,509,402   43,159,617

      Cost of sales      7,138,166    6,524,403     12,851,210   10,730,348
      Cost of sales
       - related
       parties                  --      292,040         54,493      676,209
    COST OF SALES        7,138,166    6,816,443     12,905,703   11,406,557

    GROSS PROFIT        25,806,643   19,732,290     47,603,699   31,753,060

    RESEARCH AND
     DEVELOPMENT
     EXPENSE             1,098,525      937,390      2,196,450    1,202,310

    SELLING,
     GENERAL AND
     ADMINISTRATI
'/>"/>
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
2. Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area
3. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
4. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
5. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
6. OmegaGenesis Announces Angiogenesis Application Collaboration
7. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
8. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
9. Cardiogenesis Reports Third Quarter 2008 Results
10. ThermoGenesis Presentation at Rodman & Renshaw Conference
11. Genesis Pharmaceuticals Launches New Corporate Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... SPRING, Md., July 29, 2014  United Therapeutics ... announced its financial results for the second ... continued growth shows that our medicines are ... pulmonary arterial hypertension (PAH)," said Martine Rothblatt, ... Officer. "The commercial launch this quarter of ...
(Date:7/29/2014)... The first product launch from start-up ... to robotics. What sets Droidles completely apart from other ... allows them to communicate, share code with each other ... , “The invention is the system,” said Hurley Research ... life of their own, both physically and on the ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The prestigious ... of Congress was recently awarded to Juliana Hillis and ... MA, for their project, “From an Egg, Everything: America’s ... 3,000 final entries for the National History Day program ... 300 historians and educators in Washington, D.C. , The ...
(Date:7/29/2014)... White papers by Clinovo ... eClinical technologies, have been published by leading pharmaceutical publications ... long line of white papers by Clinovo to have ... Leader, Pharmaceutical Online, and OpenHealthNews. , At the request ... CTO Marc Desgrousilliers, 'The Five Essentials of Cloud ...
Breaking Biology Technology:United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3
... , SAN MARINO, Calif., Aug. 7 ... a wholly owned subsidiary called MetaCytoLytics, Inc. This company was ... Professor M. Karen Newell called "metabolic disruption technology" (MDT), which ... from glucose or from fatty acids. That process has ...
... Aug. 6 AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported ... diluted, for the three months ended June 30, 2009, compared with ... diluted, for the three months ended June 30, 2008. For the ... or $0.02 per share basic and diluted, compared with net loss ...
... ROCKVILLE, Md., Aug. 6 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: ... and commercialization of clinical-stage product candidates for central nervous system disorders, ... 30, 2009, on Monday, August 10, 2009, before the market opens. ... that time. , , Mihael H. Polymeropoulos, M.D., ...
Cached Biology Technology:Viral Genetics Creates Subsidiary to Develop Cancer Therapy 2Viral Genetics Creates Subsidiary to Develop Cancer Therapy 3Viral Genetics Creates Subsidiary to Develop Cancer Therapy 4AutoImmune Inc. Reports 2009 Second Quarter Financial Results 2AutoImmune Inc. Reports 2009 Second Quarter Financial Results 3AutoImmune Inc. Reports 2009 Second Quarter Financial Results 4AutoImmune Inc. Reports 2009 Second Quarter Financial Results 5Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009 2
(Date:7/29/2014)... Achalasia is a rare disease it affects 1 in ... in the esophageal wall. While its cause remains unknown, a ... in Belgium, the University of Bonn in Germany and other ... autoimmune in origin. The study, published on 6 July in ... the mysterious disease. , When we swallow, a sphincter in ...
(Date:7/28/2014)... communities showing signs of damage from the Deepwater Horizon oil ... the Gulf of Mexico. The discovery was made by a ... State University. A paper describing this work and additional impacts ... will be published during the last week of July 2014 ... of the National Academy of Sciences . , "The footprint ...
(Date:7/28/2014)... Ariz. - Reactions among minerals and organic compounds in ... carbon cycle, they provide energy for the deep biosphere, ... However, very little is known about how minerals influence ... State University have demonstrated how a common mineral acts ... negating the need for toxic solvents or expensive reagents. ...
Breaking Biology News(10 mins):Mysterious esophagus disease is autoimmune after all 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Mineral magic? Common mineral capable of making and breaking bonds 2Mineral magic? Common mineral capable of making and breaking bonds 3
... Two inventions created by University of Texas Medical Branch ... Texas Ignition Fund, a new program designed to spur ... One of the inventions, conceived by UTMB anesthesiology ... to deliver precise amounts of fluids to trauma and ...
... Beijing Genomics Institute announced today that BGI has added ... sequencing technologies. Two AB SOLiD Systems have been ... The AB SOLiD System generated high-throughput high quality mate-pair ... The highest throughput reached so far is 6.8 ...
... discovered that increasing age affects the way breast cancer behaves. ... likely to be diagnosed with aggressive tumours that have spread ... increasingly likely to spread, particularly if the tumours are small. ... and lymph node involvement and this study is the first ...
Cached Biology News:UTMB inventions win University of Texas System commercialization awards 2Breast cancers behave differently before and after the age of 70 2Breast cancers behave differently before and after the age of 70 3
Human IL-19 MAb (Clone 152112)...
... (1995) This book contains up ... current issues relating to the aetiology and ... have been made recently which greatly improve ... molecular neuropathology through clinical and diagnostic aspects, ...
Complement C1r [Human]...
... Beacon Designer designs oligos for SYBR Green, ... NASBA and FRET assays. Highly specific primers ... by automatically interpreting BLAST search results. Primer ... structures identified by connecting to the Mfold ...
Biology Products: